AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Dynein regulatory complex protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96MC2

UPID:

DRC1_HUMAN

Alternative names:

Coiled-coil domain-containing protein 164

Alternative UPACC:

Q96MC2; A8K1N8; Q53R91; Q53TA3; Q8NDI5

Background:

Dynein regulatory complex protein 1, also known as Coiled-coil domain-containing protein 164, plays a pivotal role in ciliary and flagellar motility. It is a component of the nexin-dynein regulatory complex (N-DRC), crucial for maintaining the alignment and integrity of the distal axoneme. This protein is instrumental in regulating microtubule sliding in motile axonemes, assembling N-DRC, and stabilizing the assembly of inner dynein arms and radial spokes.

Therapeutic significance:

Given its critical role in ciliary and flagellar motility, Dynein regulatory complex protein 1 is directly implicated in diseases such as Primary Ciliary Dyskinesia and Spermatogenic Failure 80. Understanding the role of this protein could open doors to potential therapeutic strategies for these conditions, highlighting its significance in medical research and drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.